HomeComparePTRS vs PFE

PTRS vs PFE: Dividend Comparison 2026

PTRS yields 2.24% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PTRS wins by $38.3K in total portfolio value
10 years
PTRS
PTRS
● Live price
2.24%
Share price
$7.15
Annual div
$0.16
5Y div CAGR
44.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$87.8K
Annual income
$27,836.84
Full PTRS calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — PTRS vs PFE

📍 PTRS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPTRSPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PTRS + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PTRS pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PTRS
Annual income on $10K today (after 15% tax)
$190.21/yr
After 10yr DRIP, annual income (after tax)
$23,661.31/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PTRS beats the other by $1,341.41/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PTRS + PFE for your $10,000?

PTRS: 50%PFE: 50%
100% PFE50/50100% PTRS
Portfolio after 10yr
$68.7K
Annual income
$27,047.78/yr
Blended yield
39.38%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

PTRS
No analyst data
Altman Z
0.3
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PTRS buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPTRSPFE
Forward yield2.24%6.13%
Annual dividend / share$0.16$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR44.9%13.2%
Portfolio after 10y$87.8K$49.6K
Annual income after 10y$27,836.84$26,258.71
Total dividends collected$61.8K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PTRS vs PFE ($10,000, DRIP)

YearPTRS PortfolioPTRS Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,024$324.25$9,153$693.39+$1.9KPTRS
2$12,280$484.08$8,593$849.25+$3.7KPTRS
3$13,870$730.22$8,336$1,066.78+$5.5KPTRS
4$15,958$1,116.88$8,437$1,384.80+$7.5KPTRS
5$18,815$1,740.16$9,013$1,875.40+$9.8KPTRS
6$22,910$2,778.47$10,306$2,680.72+$12.6KPTRS
7$29,096$4,581.64$12,820$4,101.38+$16.3KPTRS
8$39,012$7,879.58$17,673$6,826.70+$21.3KPTRS
9$56,050$14,307.27$27,543$12,591.86+$28.5KPTRS
10$87,810$27,836.84$49,560$26,258.71+$38.3KPTRS

PTRS vs PFE: Complete Analysis 2026

PTRSStock

Partners Bancorp operates as the holding company for the Bank of Delmarva that provides financial services to individual and corporate customers in the United States. It offers checking, money market, NOW, IRA, savings, cash management, and time deposit accounts, as well as remote deposit capture and mobile deposit services. The company also provides commercial real estate, small business administration, term, purchase and refinance mortgage, bridge, equipment, home equity, agriculture, car, unsecured consumer, construction/permanent mortgage, and lot loans, as well as mobile home, boat, RV, and motorcycle loans; lines of credit; and business credit cards. In addition, it offers online bill payment, automated teller machine/debit card, merchant, transfer, cash advance and management, sweep, cash concentration, payroll direct deposit, and ACH origination services, as well as phone, mobile, and internet banking services. The company operates through 15 branches. The company was formerly known as Delmar Bancorp and changed its name to Partners Bancorp in August 2020. Partners Bancorp was founded in 1896 and is based in Salisbury, Maryland.

Full PTRS Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this PTRS vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PTRS vs SCHDPTRS vs JEPIPTRS vs OPTRS vs KOPTRS vs MAINPTRS vs JNJPTRS vs MRKPTRS vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.